2. NF-κB MAPK/ERK Pathway Immunology/Inflammation Stem Cell/Wnt
  3. NF-κB p38 MAPK Interleukin Related IKK JNK β-catenin Wnt
  4. Murrayafoline A

Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.

For research use only. We do not sell to patients.

Murrayafoline A

Murrayafoline A Chemical Structure

CAS No. : 4532-33-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Murrayafoline A Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All IKK Isoform Specific Products:

View All Isoforms
IKK-α IKK-β IKK IKKε TBK1

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All Wnt Isoform Specific Products:

View All Isoforms
Wnt1 Wnt3 Wnt5 Wnt7

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer[1][2][3][4].

In Vitro

Murrayafoline A (5-20 μM, 24 h) potently inhibits the production of neuroinflammation mediators, such as nitric oxide (NO), TNF-α, IL-6 and IL-1β in LPS (HY-D1056)-induced BV-2 microglial cells, an effect that can be significantly antagonized by Sp1 knockdown[1].
Murrayafoline A (20 μM, 2 h) directly interacts with Sp1, as confirmed by surface plasmon resonance (SPR) with a dissociation constant (KD) of 11.34 pM in BV-2 cells[1].
Murrayafoline A (20 μM) inhibits IKKβ/NF-κB and p38/JNK MAPKs pathways that can be markedly reversed by Sp1 knockdown in LPS-induced BV-2 cells[1].
Murrayafoline A (1-5 μM, 24 h) inhibits PDGF-BB-stimulated proliferation of vascular smooth muscle cells (VSMCs), DNA synthesis and induces a G0/G1-phase arrest[2].
Murrayafoline A (1-5 μM) down-regulates the expression of cyclin D1, cyclin E, CDK2, CDK4, and PCNA, and inhibits the phosphorylation of pRb in PDGF-BB-stimulated VSMCs[2].
Murrayafoline A (5-40 μM, 15 h) dose-dependently reduces LiCl- and Wnt3a-CM-induced TOPFlash reporter activity and SEAP activity in HEK293 reporter cells without affecting FOPFlash activity[3].
Murrayafoline A (20-40 μM, 15 h) decreases cytosolic β-catenin level in LiCl- and Wnt3a-CM-treated HEK293 reporter cells[3].
Murrayafoline A (10-80 μM, 15-48 h) reduces cytosolic β-catenin level, cyclin D1 and c-myc levels in SW480 and HCT-116 colon cancer cells and dose-dependently inhibits the proliferation of SW480, DLD-1, HCT-116 and LS174T colon cancer cells[3].
Murrayafoline A (25 μM, 2 min) increases cell shortening, increases L-type Ca2+ current, enhances PKC phosphorylation and enhances the rate of contraction in rat ventricular myocytes[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Murrayafoline A Related Antibodies

Cell Cycle Analysis[2]

Cell Line: Vascular smooth muscle cells (VSMCs)
Concentration: 1, 3, 5 μM
Incubation Time: 24 h
Result: Increased the cell population in G0/G1phase.
Decreased the S, G2, and M phases.

Cell Cycle Analysis[3]

Cell Line: SW480, DLD-1, HCT-116 and LS174T colon cancer cells
Concentration: 5, 10, 20, 40, 80 μM
Incubation Time: 48 h
Result: Inhibited the proliferation of SW480, DLD-1, HCT-116 and LS174T colon cancer cells.
In Vivo

Murrayafoline A (10-50 mg/kg, 1h pretreatment , single dose) demonstrates excellent anti-neuroinflammatory efficacy in LPS-induced neuroinflammation mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: LPS (1.5 mg/kg) was used to induce neuroinflammation in 6-7-week-old male Balb/c mice[1]
Dosage: 10, 50 mg/kg
Administration: 1h pretreatment for a single dose
Result: Reduced the expression of Iba-1, TNF-α, and IL-6 in the brains of LPS-induced male Balb/c mice.
Increased the number of Nissl bodies in the brains of LPS-induced male Balb/c mice.
Molecular Weight

211.26

Formula

C14H13NO
CAS No.
Appearance

Solid

Color

White to light yellow

SMILES

CC1=CC2=C(C(=C1)OC)NC3=CC=CC=C23
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (473.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.7335 mL 23.6675 mL 47.3350 mL
5 mM 0.9467 mL 4.7335 mL 9.4670 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (11.83 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (11.83 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.73%

SDS (418 KB)

COA (256 KB) HNMR (242 KB) LCMS (91 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.7335 mL 23.6675 mL 47.3350 mL 118.3376 mL
5 mM 0.9467 mL 4.7335 mL 9.4670 mL 23.6675 mL
10 mM 0.4734 mL 2.3668 mL 4.7335 mL 11.8338 mL
15 mM 0.3156 mL 1.5778 mL 3.1557 mL 7.8892 mL
20 mM 0.2367 mL 1.1834 mL 2.3668 mL 5.9169 mL
25 mM 0.1893 mL 0.9467 mL 1.8934 mL 4.7335 mL
30 mM 0.1578 mL 0.7889 mL 1.5778 mL 3.9446 mL
40 mM 0.1183 mL 0.5917 mL 1.1834 mL 2.9584 mL
50 mM 0.0947 mL 0.4734 mL 0.9467 mL 2.3668 mL
60 mM 0.0789 mL 0.3945 mL 0.7889 mL 1.9723 mL
80 mM 0.0592 mL 0.2958 mL 0.5917 mL 1.4792 mL
100 mM 0.0473 mL 0.2367 mL 0.4734 mL 1.1834 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Murrayafoline A Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Murrayafoline A4532-33-6NF-κBp38 MAPKInterleukin RelatedIKKJNKβ-cateninWntNuclear factor-κBNuclear factor-kappaBILIκB kinaseI kappa B kinase c-Jun N-terminal kinaseBeta cateninPlatelet-derived growth factorProliferationVascular smooth muscle cellsCell cycleinflammationvascular complicationscolon cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Murrayafoline A
Cat. No.:
HY-W100287
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (418 KB) Français - FR (418 KB) Deutsch - DE (418 KB) Norwegian - NO (418 KB) Español - ES (418 KB) Swedish - SV (418 KB) Italian - IT (418 KB) Portuguese - PT (418 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.